Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery
Latest Information Update: 12 May 2025
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Gallium 68-DOTATATE
- Indications Gastro-enteropancreatic neuroendocrine tumour; Liver metastases
- Focus Therapeutic Use
Most Recent Events
- 04 May 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jul 2025.
- 15 Sep 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 14 Jul 2023 Status changed from suspended to recruiting.